Palomino Laboratories $1.88M private stock sale
Palomino Laboratories Inc. completed a second and final closing of a private stock offering to accredited investors.
Rhea-AI Filing Summary
Palomino Laboratories Inc. completed a second and final closing of a private stock offering to accredited investors. The company sold 470,000 shares of common stock at $4.00 per share, raising gross proceeds of $1,880,000.00. This followed an initial closing of 3,773,853 shares for $15,095,412.00 at the same price.
The unregistered offering relied on Section 4(a)(2) and Rule 506 of the Securities Act. Placement agent Laidlaw & Company (UK) Ltd. received cash fees based on invested amounts and was granted 374,761 five-year warrants with a $4.80 exercise price and weighted-average anti-dilution protection.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 3.02, 9.01
2 items
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Initial closing shares: 3,773,853 shares
Initial closing proceeds: $15,095,412.00
Second closing shares: 470,000 shares
+5 more
8 metrics
Initial closing shares
3,773,853 shares
Sold in initial private placement closing at $4.00 per share
Initial closing proceeds
$15,095,412.00
Aggregate purchase price for initial closing shares
Second closing shares
470,000 shares
Sold in second, final closing at $4.00 per share
Second closing proceeds
$1,880,000.00
Gross proceeds from second closing of offering
Common stock offering price
$4.00 per share
Purchase price of common stock in both closings
Placement agent warrants
374,761 warrants
Warrants to purchase common stock issued to placement agent
Warrant exercise price
$4.80 per share
Exercise price for placement agent warrants, 120% of lowest offering price
Placement agent cash fee
10% / 5% of proceeds
Cash fees on gross proceeds by investor source at closing
Key Terms
private placement, accredited investors, Section 4(a)(2) of the Securities Act, Rule 506, +2 more
6 terms
private placement financial
"sold in an initial closing (the “Initial Closing”) of a private placement (the “Offering”)"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
accredited investors financial
"entered into subscription agreements ... with certain accredited investors and sold in an initial closing"
Accredited investors are individuals or entities considered to have enough financial knowledge and resources to understand and handle more complex and risky investments. They are often allowed to participate in private investment opportunities that are not available to the general public, similar to how experienced players might access exclusive clubs or events. This status helps ensure that investors can manage potential risks and rewards appropriately.
Section 4(a)(2) of the Securities Act regulatory
"in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act of 1933"
A legal exemption that allows a company to sell securities directly to a limited group of buyers without registering the offering with the Securities and Exchange Commission. Think of it like a private sale among known parties rather than a public auction: it can speed fundraising and reduce disclosure requirements, but it also means less public information, lower liquidity and resale restrictions—factors investors should consider when weighing risk and exit options.
Rule 506 regulatory
"Rule 506 promulgated under the Securities Act as sales to accredited investors"
A Securities and Exchange Commission rule that lets companies sell securities without registering them with the SEC when they meet certain conditions, commonly used for private placements. It allows issuers to raise unlimited capital from accredited investors and, in some versions, a small number of knowledgeable non‑accredited investors; one version also permits public advertising if the seller takes steps to verify investor credentials. For investors, it signals a private offering with lighter disclosure and different protections than a public stock sale, similar to buying into a private club rather than a publicly traded marketplace.
weighted average anti-dilution protection financial
"The Placement Agent Warrants have “weighted average” anti-dilution protection, subject to customary exceptions"
Equity Incentive Plan financial
"including but not limited to issuances of awards under the 2025 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Palomino Laboratories (PALX) disclose in this 8-K filing?
Palomino Laboratories disclosed completion of a second and final closing of a private stock offering to accredited investors, selling 470,000 common shares at $4.00 each for $1,880,000.00 in gross proceeds, following an earlier $15,095,412.00 initial closing.
How much capital did Palomino Laboratories (PALX) raise in the second closing?
In the second closing, Palomino Laboratories raised gross proceeds of $1,880,000.00. This came from selling 470,000 shares of common stock at a purchase price of $4.00 per share to accredited investors in a private placement exempt from registration.
Under which Securities Act exemptions did Palomino Laboratories (PALX) sell these shares?
The shares were sold without registration under the Securities Act in reliance on Section 4(a)(2) and Rule 506. These provisions allow private offerings to accredited investors, subject to specific conditions, instead of a registered public offering process.
What compensation did the placement agent receive in Palomino Laboratories’ offering?
Laidlaw & Company (UK) Ltd. earned cash fees of 10% or 5% of gross proceeds depending on investor introduction, plus 2% or 1% expense reimbursements, and received 374,761 five-year warrants exercisable at $4.80 per share with weighted-average anti-dilution protection.
What are the key terms of the placement agent warrants issued by Palomino Laboratories?
Palomino Laboratories issued 374,761 placement agent warrants exercisable for five years at an exercise price of $4.80 per share. The warrants include weighted-average anti-dilution protection, subject to customary exceptions such as issuances under the 2025 Equity Incentive Plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
